Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brent Wiersema

Orthopaedic Trauma Traverse City, MI Doctor of Osteopathy

NPI 1790709632 CMS profile 171795

4045 W Royal Dr, Traverse City, MI 49684

Open in the dashboard

General payments

$415

10 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brent Wiersema of Traverse City, MI is reported in the CMS Open Payments database as having received $415 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 9th percentile of Orthopaedic Trauma profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $32 1
2023 General $55 3
2021 General $49 1
2020 General $82 2
2019 General $198 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brent Wiersema
  • Orthopaedic Trauma median
  • Middle half of Orthopaedic Trauma
  • National median

In program year 2025, general payments to Brent Wiersema were reported at $32. Among 734 Orthopaedic Trauma profiles paid that year, the median was $1,227 and the middle half received between $259 and $7,433.

Show as a table
Year Brent Wiersema Orthopaedic Trauma median Middle half National median
2019 $198 $1,475 $264–$6,401 $163
2020 $82 $596 $120–$4,020 $114
2021 $49 $919 $171–$4,697 $132
2022 $0 $1,547 $272–$7,240 $149
2023 $55 $1,330 $247–$5,875 $160
2024 $0 $1,288 $277–$6,797 $164
2025 $32 $1,227 $259–$7,433 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. DePuy Synthes Sales Inc. $174 4 payments
  2. Zimmer Biomet Holdings, Inc. $96 1 payment
  3. Smith+Nephew, Inc. $90 2 payments
  4. Stryker Corporation $55 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $415 10 payments
Products named General payments · program years 2019–2025
  1. BME NITINOL CONTINUOUS COMPRESSION IMPLANTS $143 3 payments
  2. Hips Product Portfolio $96 1 payment
  3. MyMobility $96 1 payment
  4. CORI $49 1 payment
  5. Legion Revision $41 1 payment
  6. Journey II BCS $41 1 payment
  7. POLARSTEM $41 1 payment
  8. R3 $41 1 payment
  9. MAKO $36 2 payments
  10. LCP $32 1 payment
  11. Other $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

250

Median for Orthopedic Surgery: 203

Drug cost

$965

Median for Orthopedic Surgery: $1,433

Branded share of claims

25.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 63 $389
Omeprazole Generic 31 $124
Meloxicam Generic 66 $120
Mupirocin Generic 17 $108
Oxycodone Hcl Generic 18 $76
Cephalexin Generic 20 $74
Tramadol Hcl Generic 24 $56
Amoxicillin Generic 11 $18

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$129,531

Of which drugs: $1,590

Medicare patients

314

Average age 74

Services billed

2,715

178 women, 136 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Diabetes 22%
Ischemic heart disease 22%
Depression 22%
Chronic kidney disease 19%
Cancer 18%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 35 1,640 $158
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 29 125 $93

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Trauma in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record